Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Hydroxychloroquine Versus COVID-19: A Periodic Systematic Review and Meta-Analysis

View ORCID ProfileAmir Shamshirian, View ORCID ProfileAmirhossein Hessami, View ORCID ProfileKeyvan Heydari, View ORCID ProfileReza Alizadeh-Navaei, View ORCID ProfileMohammad Ali Ebrahimzadeh, View ORCID ProfileGeorge W. Yip, View ORCID ProfileRoya Ghasemian, Morteza Behnamfar, View ORCID ProfileHananeh Baradaran, Elham Aboufazeli, Hamed Jafarpour, Keyvan Karimifar, Aida Eftekhari, View ORCID ProfileDanial Shamshirian
doi: https://doi.org/10.1101/2020.04.14.20065276
Amir Shamshirian
1Department of Medical Laboratory Sciences, Student Research Committee, School of Allied Medical Science, Mazandaran University of Medical Sciences, Sari, Iran
2Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Amir Shamshirian
Amirhossein Hessami
3Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
4Systematic Review and Meta-Analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Amirhossein Hessami
Keyvan Heydari
2Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran
3Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Keyvan Heydari
Reza Alizadeh-Navaei
2Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Reza Alizadeh-Navaei
  • For correspondence: shamshirian@sbmu.ac.ir reza_nava@yahoo.com
Mohammad Ali Ebrahimzadeh
4Systematic Review and Meta-Analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mohammad Ali Ebrahimzadeh
George W. Yip
6Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for George W. Yip
Roya Ghasemian
7Antimicrobial Resistance Research Center, Department of Infectious Diseases, Mazandaran University of Medical Sciences, Sari, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Roya Ghasemian
Morteza Behnamfar
8Student Research Committee, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hananeh Baradaran
9Clinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hananeh Baradaran
Elham Aboufazeli
10Department of Research and Development, IRAN NAJO Pharmaceutical Company, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hamed Jafarpour
3Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keyvan Karimifar
11Student Research Committee, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aida Eftekhari
11Student Research Committee, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Danial Shamshirian
12Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Danial Shamshirian
  • For correspondence: shamshirian@sbmu.ac.ir reza_nava@yahoo.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Importance This systematic review and meta-analysis not only indicated no clinical benefits regarding hydroxychloroquine (HCQ) treatment with/without azithromycin for COVID-19 patients, but the higher mortality rate and frequency of known HCQ adverse effects were observed for the HCQ/HCQ+AZM regimen group.

Objective To overcome the controversies regarding the effectiveness of hydroxychloroquine in the treatment of COVID-19 through meta-analysis.

Data Sources A systematic search was performed in PubMed, Scopus, Embase, Cochrane Library, Web of Science, Google Scholar and medRxiv pre-print database using all available MeSH terms for COVID-19 and hydroxychloroquine up to May 14, 2020.

Study Selection Studies focused on the effectiveness of HCQ with/without azithromycin (AZM) in confirmed COVID-19 patients were entered into the study including: comparative or non-comparative clinical studies including observational/interventional studies with retrospective/prospective nature with/without control group as well as Randomized Clinical Trials (RCTs).

Data Extraction and Synthesis Two researchers have independently evaluated quality assessment of the studies and abstracted data for data extraction, which has reviewed by the supervisor for accuracy. Extracted data were analyzed using CMA v. 2.2.064. Heterogeneity was assessed using the I-squared (I2) test, and fixed/random-effects model was used when appropriate for pooling of studies.

Main Outcome(s) and Measure(s) 1) Clinical effectiveness of HCQ with/without AZM in the treatment of COVID-19; 2) Mortality rate; 3) Disease exacerbation; 4) Frequency of known HCQ adverse effects occurred during treatment; 5) Intubation need; 6) Radiological improvement.

Results Out of 21 studies entered into our systematic review, 18 studies including 11 comparative studies with control group and seven observational studies containing 5,561 participants have entered into the study. The results of the meta-analysis on comparative studies indicated no significant clinical effectiveness (negative in RT-PCR evaluation) for HCQ regimen in the treatment of COVID-19 in comparison to control group (RR: 0.96, 95% CI, 0.76-1.22). The same result was observed for the combination of HCQ+azithromycin (RR: 2.15, 95% CI, 0.31-14.77). Approximately 1.5 times higher mortality rate was observed among the HCQ regimen group (RR: 1.54, 95% CI, 1.04-2.29) and 3.5 times higher in HCQ+AZM (RR: 3.65, 95% CI, 1.10-12.10) group in comparison to control group, which was affected by age differences according to meta-regression analysis (P=0.0003). No substantial difference was observed for disease exacerbation (RR: 1.60, 95% CI, 0.54-4.71) between HCQ group and controls. Also, radiological findings significantly improved in the HCQ group (OR: 0.32, 95% CI, 0.11-0.98). Odds of known HCQ adverse effects (diarrhea, vomiting, blurred vision, rash, headache, etc.) occurred in the HCQ regimen group was approximately 3.5 times of control group (OR: 3.55, 95% CI, 1.61-7.82), but no substantial differences were found regarding intubation odds between HCQ group and control group (OR: 2.11, 95% CI, 0.31-14.03).

Conclusions and Relevance This systematic review and meta-analysis not only showed no clinical benefits regarding HCQ treatment with/without azithromycin for COVID-19 patients, but according to multiple sensitivity analysis, the higher mortality rates were observed for both HCQ and HCQ+AZM regimen groups, especially in the latter. Also, frequency of adverse effects was higher in HCQ regimen group. However, due to that most of the studies were non-randomized and results were not homogenous, selection bias was unavoidable and further large randomized clinical trials following comprehensive meta-analysis should be taken into account in order to achieve more reliable findings.

Question Is hydroxychloroquine effective and safe against COVID-19?!

Findings This systematic review and meta-analysis on 18 studies including 5,561 participants indicated no significant clinical effectiveness for hydroxychloroquine with/without azithromycin against COVID-19 patients. Also, the higher mortality rate and adverse effects were observed in the HCQ/HCQ+AZM regimen group.

Meaning It seems that hydroxychloroquine does not works as expected and attracted attentions as a potential agent against COVID-19, so, we should be cautious about the treatment decision.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

None

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data that support the findings of this study are openly available in data bases mentioned in the search strategy.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 17, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Hydroxychloroquine Versus COVID-19: A Periodic Systematic Review and Meta-Analysis
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Hydroxychloroquine Versus COVID-19: A Periodic Systematic Review and Meta-Analysis
Amir Shamshirian, Amirhossein Hessami, Keyvan Heydari, Reza Alizadeh-Navaei, Mohammad Ali Ebrahimzadeh, George W. Yip, Roya Ghasemian, Morteza Behnamfar, Hananeh Baradaran, Elham Aboufazeli, Hamed Jafarpour, Keyvan Karimifar, Aida Eftekhari, Danial Shamshirian
medRxiv 2020.04.14.20065276; doi: https://doi.org/10.1101/2020.04.14.20065276
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Hydroxychloroquine Versus COVID-19: A Periodic Systematic Review and Meta-Analysis
Amir Shamshirian, Amirhossein Hessami, Keyvan Heydari, Reza Alizadeh-Navaei, Mohammad Ali Ebrahimzadeh, George W. Yip, Roya Ghasemian, Morteza Behnamfar, Hananeh Baradaran, Elham Aboufazeli, Hamed Jafarpour, Keyvan Karimifar, Aida Eftekhari, Danial Shamshirian
medRxiv 2020.04.14.20065276; doi: https://doi.org/10.1101/2020.04.14.20065276

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (227)
  • Allergy and Immunology (502)
  • Anesthesia (110)
  • Cardiovascular Medicine (1234)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (530)
  • Epidemiology (10015)
  • Forensic Medicine (5)
  • Gastroenterology (499)
  • Genetic and Genomic Medicine (2449)
  • Geriatric Medicine (236)
  • Health Economics (479)
  • Health Informatics (1638)
  • Health Policy (751)
  • Health Systems and Quality Improvement (636)
  • Hematology (248)
  • HIV/AIDS (532)
  • Infectious Diseases (except HIV/AIDS) (11862)
  • Intensive Care and Critical Care Medicine (625)
  • Medical Education (252)
  • Medical Ethics (74)
  • Nephrology (268)
  • Neurology (2278)
  • Nursing (139)
  • Nutrition (350)
  • Obstetrics and Gynecology (453)
  • Occupational and Environmental Health (535)
  • Oncology (1245)
  • Ophthalmology (375)
  • Orthopedics (133)
  • Otolaryngology (226)
  • Pain Medicine (155)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (729)
  • Pharmacology and Therapeutics (311)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2280)
  • Public and Global Health (4829)
  • Radiology and Imaging (834)
  • Rehabilitation Medicine and Physical Therapy (490)
  • Respiratory Medicine (651)
  • Rheumatology (283)
  • Sexual and Reproductive Health (237)
  • Sports Medicine (226)
  • Surgery (266)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)